Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Clin Pharmacol ; 73(11): 1491-1497, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28795244

ABSTRACT

PURPOSE: The anticoagulant effect of warfarin used to treat stroke has been shown to vary with the concomitant use of medications and comorbidity. Concomitant use of antithrombotic drugs and underlying chronic kidney disease (CKD) represent risk factors for bleeding events. We conducted a comprehensive investigation of the background characteristics and concomitant use of drugs to identify the risk factors for warfarin-related bleeding, focusing on renal function. METHODS: The study population consisted of patients prescribed warfarin at the Tokyo Women's Medical University Hospital. A retrospective review of the patient data, including bleeding events, bleeding sites, the patient's background, concomitant use of drugs, and laboratory data was carried out, and the incidence of bleeding events was compared in patient groups stratified according to CKD stage and antithrombotic drug use. Multivariate logistic regression analysis was performed to determine the risk factors for warfarin-related bleeding. RESULTS: Of the 3,831 patients included in the study, the incidence of warfarin-related bleeding was 3.0 events per 100 patient-years. The multivariate logistic regression analysis identified age > 65 years, body mass index (BMI), alanine aminotransferase (ALT), estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2, prothrombin time-international normalized ratio (PT-INR), and concomitant use of antithrombotic drugs as risk factors for warfarin-related bleeding. CONCLUSIONS: The present analyses identified age > 65 years, BMI, ALT, eGFR <30 mL/min/1.73 m2, PT-INR, and concomitant use of antithrombotic drugs as independent risk factors for warfarin-related bleeding. We should pay attention to the risk factors associated with warfarin-related bleeding when prescribing warfarin in patients with renal impairment.


Subject(s)
Anticoagulants/adverse effects , Hemorrhage/chemically induced , Kidney/physiology , Warfarin/adverse effects , Aged , Alanine Transaminase/blood , Body Mass Index , Female , Fibrinolytic Agents/therapeutic use , Glomerular Filtration Rate , Hemorrhage/blood , Hemorrhage/epidemiology , Hemorrhage/physiopathology , Humans , International Normalized Ratio , Male , Middle Aged , Prothrombin Time , Renal Insufficiency, Chronic/blood , Renal Insufficiency, Chronic/drug therapy , Renal Insufficiency, Chronic/epidemiology , Renal Insufficiency, Chronic/physiopathology , Retrospective Studies , Risk Factors
2.
J Biol Chem ; 291(33): 17228-46, 2016 08 12.
Article in English | MEDLINE | ID: mdl-27325700

ABSTRACT

At the onset of anaphase, a protease called separase breaks the link between sister chromatids by cleaving the cohesin subunit Scc1. This irreversible step in the cell cycle is promoted by degradation of the separase inhibitor, securin, and polo-like kinase (Plk) 1-dependent phosphorylation of the Scc1 subunit. Plk could recognize substrates through interaction between its phosphopeptide interaction domain, the polo-box domain, and a phosphorylated priming site in the substrate, which has been generated by a priming kinase beforehand. However, the physiological relevance of this targeting mechanism remains to be addressed for many of the Plk1 substrates. Here, we show that budding yeast Plk1, Cdc5, is pre-deposited onto cohesin engaged in cohesion on chromosome arms in G2/M phase cells. The Cdc5-cohesin association is mediated by direct interaction between the polo-box domain of Cdc5 and Scc1 phosphorylated at multiple sites in its middle region. Alanine substitutions of the possible priming phosphorylation sites (scc1-15A) impair Cdc5 association with chromosomal cohesin, but they make only a moderate impact on mitotic cell growth even in securin-deleted cells (pds1Δ), where Scc1 phosphorylation by Cdc5 is indispensable. The same scc1-15A pds1Δ double mutant, however, exhibits marked sensitivity to the DNA-damaging agent phleomycin, suggesting that the priming phosphorylation of Scc1 poses an additional layer of regulation that enables yeast cells to adapt to genotoxic environments.


Subject(s)
Cell Cycle Proteins/metabolism , Chromosomal Proteins, Non-Histone/metabolism , DNA Damage , Mitosis , Protein Serine-Threonine Kinases/metabolism , Saccharomyces cerevisiae Proteins/metabolism , Saccharomyces cerevisiae/metabolism , Amino Acid Substitution , Cell Cycle Proteins/genetics , Chromosomal Proteins, Non-Histone/genetics , Mutation, Missense , Phleomycins/pharmacology , Phosphorylation/genetics , Protein Serine-Threonine Kinases/genetics , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins/metabolism , Saccharomyces cerevisiae/genetics , Saccharomyces cerevisiae Proteins/genetics , Cohesins , Polo-Like Kinase 1
3.
Nat Commun ; 6: 7815, 2015 Jul 23.
Article in English | MEDLINE | ID: mdl-26204128

ABSTRACT

Chromosome condensation is a hallmark of mitosis in eukaryotes and is a prerequisite for faithful segregation of genetic material to daughter cells. Here we show that condensin, which is essential for assembling condensed chromosomes, helps to preclude the detrimental effects of gene transcription on mitotic condensation. ChIP-seq profiling reveals that the fission yeast condensin preferentially binds to active protein-coding genes in a transcription-dependent manner during mitosis. Pharmacological and genetic attenuation of transcription largely rescue bulk chromosome segregation defects observed in condensin mutants. We also demonstrate that condensin is associated with and reduces unwound DNA segments generated by transcription, providing a direct link between an in vitro activity of condensin and its in vivo function. The human condensin isoform condensin I also binds to unwound DNA regions at the transcription start sites of active genes, implying that our findings uncover a fundamental feature of condensin complexes.


Subject(s)
Adenosine Triphosphatases/metabolism , Chromosomes/metabolism , DNA-Binding Proteins/metabolism , Multiprotein Complexes/metabolism , Schizosaccharomyces/metabolism , Transcription, Genetic , Genome , HeLa Cells , Humans , Mitosis , RNA Polymerase II/metabolism
4.
Curr Biol ; 25(13): 1694-706, 2015 Jun 29.
Article in English | MEDLINE | ID: mdl-26051894

ABSTRACT

Sister chromatid cohesion is mediated by cohesin and is essential for accurate chromosome segregation. The cohesin subunits SMC1, SMC3, and Rad21 form a tripartite ring within which sister chromatids are thought to be entrapped. This event requires the acetylation of SMC3 and the association of sororin with cohesin by the acetyltransferases Esco1 and Esco2 in humans, but the functional mechanisms of these acetyltransferases remain elusive. Here, we showed that Esco1 requires Pds5, a cohesin regulatory subunit bound to Rad21, to form cohesion via SMC3 acetylation and the stabilization of the chromatin association of sororin, whereas Esco2 function was not affected by Pds5 depletion. Consistent with the functional link between Esco1 and Pds5, Pds5 interacted exclusively with Esco1, and this interaction was dependent on a unique and conserved Esco1 domain. Crucially, this interaction was essential for SMC3 acetylation and sister chromatid cohesion. Esco1 localized to cohesin localization sites on chromosomes throughout interphase in a manner that required the Esco1-Pds5 interaction, and it could acetylate SMC3 before and after DNA replication. These results indicate that Esco1 acetylates SMC3 via a mechanism different from that of Esco2. We propose that, by interacting with a unique domain of Esco1, Pds5 recruits Esco1 to chromatin-bound cohesin complexes to form cohesion. Furthermore, Esco1 acetylates SMC3 independently of DNA replication.


Subject(s)
Acetyltransferases/metabolism , Cell Cycle Proteins/metabolism , Chromatids/metabolism , Chromosomal Proteins, Non-Histone/metabolism , DNA Replication/physiology , Nuclear Proteins/metabolism , Acetylation , Amino Acid Sequence , Chondroitin Sulfate Proteoglycans/metabolism , HeLa Cells , Humans , Immunoblotting , Immunoprecipitation , Molecular Sequence Data , Nuclear Proteins/genetics , Cohesins
5.
Biol Pharm Bull ; 35(1): 10-7, 2012.
Article in English | MEDLINE | ID: mdl-22223331

ABSTRACT

The effects of six lipophilic vitamins: tretinoin (ATRA), vitamin D(3) (VD(3)), VE, VK(1), VK(3), and VK(5) on cell proliferation and apoptosis in human A375 melanoma cells were investigated. VD(3), VK(3), and VK(5) were found to inhibit cell proliferation significantly at concentration ranges of 10-100 µmol/L (p<0.01), while the other vitamins did not show inhibitory effects at 100 µmol/L. VK(3) and VK(5) showed the strongest effects with IC(50) values of less than 10 µmol/L. Dacarbazine slightly inhibited the proliferation of A375 cells at a concentration range of 25-100 µmol/L, but the effects were not statistically significant. VK(3) and VK(5) increased annexin-V positive apoptotic cells, as well as activating caspase-3, in A375 cells. Our findings showed that VD(3), VK(3,) and VK(5) inhibited the growth of dacarbazine resistant human melanoma cells, while ATRA, VE, and VK(1) had little effect on the cell growth. The effects of VK(3) and VK(5) were observed at concentrations lower than 10 µmol/L, which are suggested to have resulted from apoptosis-induction in the melanoma cells.


Subject(s)
Antineoplastic Agents/therapeutic use , Apoptosis/drug effects , Cholecalciferol/therapeutic use , Drug Resistance, Neoplasm/drug effects , Melanoma/drug therapy , Tretinoin/therapeutic use , Vitamin K/therapeutic use , Annexin A5/metabolism , Antineoplastic Agents/pharmacology , Caspase 3/metabolism , Cell Line, Tumor , Cell Proliferation/drug effects , Cholecalciferol/pharmacology , Dacarbazine/pharmacology , Dacarbazine/therapeutic use , Humans , Hydrophobic and Hydrophilic Interactions , Inhibitory Concentration 50 , Melanoma/metabolism , Tretinoin/pharmacology , Vitamin K/pharmacology , Vitamins/pharmacology , Vitamins/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...